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Abstract
Autologous chondrocyte implantation is a surgical technique utilized for repair of artic-
ular cartilage defects. The originally described technique for autologous chondrocyte 
implantation involves applying a liquid suspension of the cultured chondrocytes to a 
cartilage defect and sealing the defect with a periosteum or collagen patch. Scaffolds for 
housing chondrocytes were introduced to allow for increased ease of delivery and appli-
cation, to avoid leakage of chondrocytes out of the defect, and to allow for an implant that 
more closely mimics the non-uniform tissue architecture of healthy articular cartilage. In 
this chapter we describe the design, clinical outcomes, and commercial availability of var-
ious scaffolds reported in the clinical literature for autologous chondrocyte implantation.
Keywords: scaffold, MACI, MACT, autologous chondrocyte implantation, 3rd generation 
ACI
1. Introduction
Autologous chondrocyte implantation (ACI) is a two-stage articular cartilage repair technique 
for treatment of articular cartilage defects. Originally described by Brittberg et al. [1], it involves 
an initial surgery to harvest chondrocytes from a non-weight bearing portion of the distal femur, 
typically the intercondylar notch or medial or lateral margin of the trochlea. The cartilage extra-
cellular matrix is then enzymatically digested within the laboratory to isolate the chondrocytes. 
The harvested chondrocytes are then cultured in a laboratory. In the second stage, a liquid sus-
pension of chondrocytes is applied to the cartilage defect and is sealed in place with a soft tissue 
membrane cover [1]. Originally periosteum was utilized as the cover, though a collagen mem-
brane was later introduced to minimize periosteal donor site morbidity and risk of periosteal 
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patch hypertrophy [2]. Disadvantages of ACI with periosteum or collagen membrane covers 
with the use of a liquid cultured chondrocyte suspension include a high degree of technical dif-
ficulty, potential for leakage of chondrocytes, and non-uniform distribution of chondrocytes.
Scaffolds for housing chondrocytes were introduced for increased ease of delivery and appli-
cation, to avoid leakage of chondrocytes out of the defect, and to allow homogeneous dis-
tribution of chondrocytes within the defect [3]. Additionally, there is some evidence that 
chondrocytes grown in monolayer culture do not fully regain their original phenotype [3, 4], 
which has prompted research in culture directly within a scaffold and design of implants that 
more closely mimics the non-uniform tissue architecture of healthy articular cartilage [3]. Use 
of a 3-dimensional structure for chondrocyte culture has been shown to maintain the chon-
drocyte differentiated phenotype [5]. Use of a scaffold is termed ‘matrix-assisted autologous 
chondrocyte transplantation,’ or the MACT procedure, and has been employed in clinical 
practice in Europe since 1998. The MACT procedure involves implantation of a chondrocyte 
seeded biocompatible scaffold in the articular defect [2]. The implant is fixed in place with 
fibrin glue with no membrane cover and allows for implantation with use of a mini-arthrot-
omy or arthroscopic implantation. The field of scaffold-based ACI has greatly expanded in 
recent years, with more than a dozen implants developed (Table 1). A wide variety of natural 
and synthetic materials have been utilized in MACT scaffolds; though clinical outcomes stud-
ies are generally favorable regardless of scaffold design, the number or published studies and 
length of follow-up vary widely among implants.
In this chapter, the design rationale, commercial availability, and clinical results of various 
scaffolds for use in MACT will be described. Of note, all implants described in this chapter 
follow a two-step implantation protocol (initial cartilage harvest and culturing of chondro-
cytes followed by a delayed implantation several weeks later). The single-stage implantation 
techniques with published outcomes data are either no longer commercially available (the 
CAIS implant) [6], or have yet to be marketed [7].
Scaffold content Commercial name Implantation steps
Porcine collagen I/III membrane MACI Two-steps
Three-dimensional collagen I based scaffold NeoCart Two-steps
Three-dimensional collagen I based scaffold CaReS Two-steps
Three-dimensional collagen I based scaffold Novocart 3D Two-steps
Hyaluronic acid based scaffold Hyalograft C Two-steps
Human fibrin and recombinant hyaluronic acid-based scaffold BioCart II Two-steps
Fibrin based gel Chondron Two-steps
Hydrogel of agarose and alginate Cartipatch Two-steps
Atelocollagen gel Koken Atelocollagen Implant Two-steps
Fibrin, polyglycolic/polylactic acid, polydioxanone BioSeed-C Two-steps
Table 1. Summary of MACT scaffolds.
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2. Scaffolds utilized for autologous chondrocyte implantation
2.1. Porcine collagen I/III membranes
2.1.1. MACI
As of December 2016, matrix-assisted chondrocyte implantation (MACI; Vericel, Cambridge, 
MA) is currently the only FDA approved MACT technique for use in the United States. 
In this technique, chondrocytes are cultured ex-vivo in a monolayer and then seeded on 
one side of a porcine collagen I/III membrane (Table 2). At the second stage operation (re-
implantation), the side seeded with chondrocytes (the roughened side) is placed against 
the subchondral bone surface and the graft is secured with fibrin glue [8]. The implantation 
may be performed arthroscopically or with a mini-arthrotomy, and recent work demon-
strates MACI grafts may be safely applied with use of carbon dioxide insufflation arthros-
copy [9]. Regardless of technique, gentle handling of the graft is recommended, as excessive 
or forceful handling of the graft causes a significant decrease in viable chondrocytes [10]. A 
histologic study of 56 MACI patients up to 6 months after surgery demonstrated that chon-
drocytes appeared well-integrated and maintained chondrocyte phenotype [11]. Hyaline-
like cartilage production began as early as 21 days after implantation, and there was 75% 
hyaline-like cartilage regeneration at 6 months [11]. Another histologic study of 33 second-
look biopsies at median 15 months after surgery found a median ICRS histological grade of 
57 which did not correlate with an arthroscopic ICRS grade of normal in 30% of cases and 
nearly normal in 51% of cases [12].
Several comparative studies have been performed with MACI, all of which demonstrated 
encouraging results (Table 3). However, it should be noted that use of MACI in clinical 
practice tends to be in larger defects (mean 5.64 cm2) than lesions treated in clinical trials 
(weighted mean 4.89 cm2) [13]. Approval by the FDA was based primarily on results of the 
SUMMIT trial, reported by Saris et al. [14]. In this randomized trial, 144 patients with high 
grade femoral condylar defects were randomized to MACI or microfracture and followed for 
2 years; mean defect size was equivalent between groups (4.9 cm2 MACI vs. 4.7 cm2 micro-
fracture) [14]. At final follow-up there was significantly better improvement in KOOS symp-
tom scores with MACI, lower failure rates, yet no difference in repair quality as assessed by 
histology or MRI versus microfracture [14]. A randomized controlled trial was performed by 
Bartlett et al. with comparison of ACI-C (ACI with collagen cover) and MACI for treatment 
Commercial 
name
Manufacturer Structure Expansion Availability
MACI Vericel, Cambridge, MA (Formerly 
provided by Verigen Transplantation 
Service, Copenhagen, Denmark)
Porcine-
derived 
collagen I/III 
bilayer
Cells are expanded in 
monolayer then seeded 
onto porous side of 
collagen membrane
FDA approved 
for use in the 
USA. Available in 
Europe and Australia
FDA, U.S. Food and Drug Administration.
Table 2. MACT with porcine collagen I/III membrane scaffold.
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of high grade chondral defects. Mean defect size was 6.0 cm2 for the MACI group and 6.1 cm2 
for the ACI-C group [8]. At 1 year follow-up both groups demonstrated significant improve-
ment in Cincinnati knee scores and similar re-operation rates (9% for both groups) [8]. Basad 
et al. performed a randomized study of MACI versus microfracture with 2 years follow-up on 
high grade defects 4–10 cm2 [15]. The MACI group in this study had greater improvements in 
symptom scores, activity scores, and ICRS surgeon grading of cartilage appearance at second 
look arthroscopy [15]. In a comparative imaging and clinical study of MACI versus osteo-
chondral autograft transfer (OAT) by Salzmann et al., superior Lysholm symptoms scores 
were observed in the MACI group; patients in this study were matched for demographics, 
but MACI-treated lesions were >3 cm2 and OAT-treated lesions were <3 cm2 [16]. For treat-
ment of chondromalacia patella, Macmull et al. noted a higher rate of good-excellent patient 
symptom scores with MACI (56.5%) than ACI-C (40%). Higher rates of clinical failure (poor 
patient-rated symptoms) were noted with lateral facet lesions, and the authors did not report 
distribution of lesions (medial facet, lateral facet, or multiple facets) by treatment group [17]. 
Finally, Akgun et al. report a small randomized trial of MACI versus autologous mesenchy-
mal stem cells (also seeded onto a collagen scaffold) with 2 years follow-up [18]. The stem 
cell group had greater symptom improvement at 6 months but similar improvement at final 
follow-up; no clinical failures were noted in either group [18].
Level of 
evidence
Author Implant and sample 
size
Mean follow-up Outcome
1 Ebert et al. [20] 19 MACI-standard 
WB; 18 MACI-
accelerated WB
2 years Randomized trial of standard 8 week 
return to weight bearing versus 
accelerated 6 week return to weight 
bearing. No difference in symptom 
improvement.
1 Wondrasch et al. 
[21]
15 MACI-standard 
WB; 16 MACI-
accelerate WB
5 years Randomized trial of 6 versus 10 week 
return to weight bearing. No difference 
in symptom improvement between 
groups. MOCART score decreased from 
years 2 to 5 which did not correlate with 
symptom scores
1 Akgun et al. [18] 7 MACI; seven 
mesenchymal stem 
cell
2 years Small randomized trial of MACI versus 
stem cells (also seeded onto a collagen 
scaffold. Stem cell group had greater 
symptom improvement at 6 months but 
similar improvement at final follow-up.
1 Basad et al. [15] 40 MACI; 20 
microfracture
2 years At 24 months, greater improvements 
seen with MACI in Tegner activity 
score, subjective symptoms scores and 
ICRS scores on 2nd look arthroscopy.
1 Saris et al. [14] 72 MACI; 72 
microfracture
2 years Greater improvement in KOOS scores, 
lower failure rate with MACI (12.5%) 
versus microfracture (31.9%). Similar 
MRI and histologic outcomes.
Table 3. Outcomes of MACT with collagen I/III membrane scaffold (MACI) from level 1 prospective clinical studies.
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Several randomized trials of delayed versus accelerated weight-bearing after MACI have been 
performed (Table 3). A randomized trial of 6 week versus 8 week return to full weight bearing 
found no significant difference in failure rates or symptom improvement at 2 years (interim 
12-month results reported in an earlier publication [19]); the study authors concluded acceler-
ated weight bearing after MACI is safe [20]. Another trial of 6 week versus 10 week return to 
full weight bearing with 5 years follow-up after MACI similarly found no difference in symp-
tom improvement between groups [21]. The authors note that MRI-based MOCART scores 
decreased from years 2 to 5 but did not correlate with symptom scores [21].
Several case series have reported also reported good results with MACI (Table 3). The series 
with the longest follow-up is reported by Gille et al.; of 19 cases with mean 16 years follow-up, 
21% underwent knee arthroplasty (4/19), with durable symptom improvement in the remain-
ing 15 patients [22]. In another series of MACI patients, Basad et al. report durable improve-
ments in activity and symptoms scores and a failure rate of 18.5% at 5 years with MACI [23]. 
Behrens et al. similarly report 8/11 patients rated their current knee function as ‘much better 
or better’ than their pre-operative function at 5 years follow-up [24]. A larger case series by 
Ebert et al. of 41 patients and 5 years follow up (35/41, 85% with 5 years follow-up) reported 
significant improvements in knee function, a 12% rate of graft hypertrophy at 5 years, and a 
graft failure rate of 3% at 5 years [25]. Durable results are seen with arthroscopic implantation 
of MACI scaffolds, as Ebert et al. report stable clinical improvement at 5 years follow-up and 
a failure rate of 6.4% [26]. Ventura et al. note improvement in Lysholm symptom scores at 
2 years but no change in Tegner activity scores in a series of 53 patients; a high rates of sub-
chondral abnormalities were noted on MRI at 1 year (70% of cases) which did not correlate 
with clinical symptoms [27].
For the patellofemoral joint, Meyerkort et al. report durable improvement in symptoms at 
5 years with MACI; clinical improvement did not correlate with MRI assessment of graft 
appearance at 5 years [28]. Gigante et al. published results of treatment of patellar defects 
with MACI and concomitant distal realignment; at 3 years, there was significant improvement 
in symptoms in most patients and one clinical failure (7%) [29].
As a salvage operation in young patients with medial compartment osteoarthritis, Bauer et al. 
report significant clinical improvement at 5 years with combined high tibial osteotomy and 
MACI; however, they note declining results and high graft failure over time for this salvage 
operation [30]. Finally, outcomes for MACI and concomitant bone grafting for treatment of 
osteochondral lesions with use of a bilayer ‘sandwich’ technique have also been reported. 
Vijayan et al. report outcomes with use of two MACI membranes and impaction bone graft-
ing of osteochondral lesions greater than 8 mm depth; at a mean 5.2 year’s follow-up, 12/14 
patients had good to excellent results with one graft failure [31].
2.2. Three-dimensional collagen I based scaffolds
2.2.1. NeoCart
NeoCart (Histogenics Corporation, Waltham, Massachusetts) is an MACT implant that con-
sists of a three-dimensional bovine collagen I scaffold (Table 4). Rather than being cultured 
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in a monolayer, the scaffold is seeded initially with chondrocytes which then proliferate in 
a custom bioreactor [32]. The bioreactor is designed to incubate the scaffold in a low-oxygen 
tension environment with varying pressure to mimic the native intra-articular environment 
with the goal of preserving the chondrocyte phenotype [33]. At the time of implantation, the 
graft is fixed to the defect with a proprietary adhesive (CT3 bioadhesive, Histogenics). A ran-
domized phase II trial by Crawford et al. of distal femoral lesions treated with NeoCart versus 
microfracture demonstrated superior improvement in IKDC and KOOS scores at 24 months 
with NeoCart and no difference in adverse events between groups (Table 5) [33]. A small case 
series (8 patients) with 2 years follow-up demonstrated significant symptom improvement 
from baseline and no cases of graft hypertrophy or arthrofibrosis (Table 5) [32]. Defect fill 
was noted to be moderate (33–66%) in 1/8 cases and poor (<33%) in 1/8 cases. A longitudinal 
Level of 
evidence
Author Implant and 
sample size
Mean 
follow-up
Outcome
1 Crawford et al. [33] 21 NeoCart; 9 
microfracture
2 years Randomized trial of distal femoral lesions. 
Greater IKDC and KOOS improvement at 
2 years with NeoCart.
3 Flohe et al. [35] 9 CaReS; 11 
MACI
1 year No difference in clinical outcomes between 
groups.
3 Petri et al. [36] 17CaReS; 10 
microfracture
3 years Comparative trial for patellofemoral defects. 
No difference in groups between IKDC, SF-36, 
or Cincinnati knee scores at 3 years follow-up.
Table 5. MACT clinical outcome studies with three-dimensional collagen 1 scaffold.
Commercial 
name
Manufacturer Structure Expansion Availability
NeoCart Histogenics Corporation, 
Waltham, Massachusetts
Bovine collagen type 
I matrix
Cells are 
expanded directly 
on 3D scaffold 
via a custom 
bioreactor
Ongoing phase III clinical 
trials; not yet approved by 
the FDA
CaReS Arthro Kinetics (Ars 
Arthro, Esslingen, 
Germany)
Rat collagen type I 
matrix
Cells are mixed 
with collagen 
which forms a gel 
and cultured for 
2 weeks
SFDA certified; not yet 
approved by the FDA
Novocart 3D B. Braun-Tetec, 
Reutlingen, Germany
Collagen-
chondroitin sulfate 
scaffold
Initial monolayer 
culture followed 
by seeding 
onto scaffold; 
re-implantation 
3–4 weeks after 
harvest
Available in Europe, 
ongoing phase III clinical 
trials.
FDA, U.S. Food and Drug Administration; SFDA, State Food and Drug Administration of China; 3D, three-dimensional.
Table 4. MACT with three-dimensional collagen 1 scaffold.
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clinical and MRI-based study with 5 years follow-up by Anderson et al. demonstrate that 
clinical improvement and graft appearance on MRI both evolve over the first 24 months after 
surgery [34]. Both clinical scores and MRI appearance appeared stable from 24 to 60 months 
follow-up [34].
2.2.2. CaReS
The Cartilage Regeneration System (CaReS, Ars Arthro, Esslingen, Germany) utilizes a rat-
derived collagen I gel rather than the bovine collagen matrix utilized by NeoCart (Table 4). 
The harvested chondrocytes are similarly seeded into the collagen gel and cultured in this 
3-dimensional environment with the intention of preserving cartilage phenotype. In a small 
comparative study of CaReS (9 patients) versus MACI (11 patients) with 1 year follow-up, 
Flohe et al. demonstrate significant improvement in symptoms with no difference between 
groups (Table 5) [35]. A small comparative study of microfracture (n = 10) vs. CaReS (n = 17) 
for patellofemoral lesions found significant improvements in symptoms from baseline with 
no difference in outcomes between groups [36]. In a multicenter clinical trial, Schneider et al. 
report outcomes of 116 at mean 30.6 month follow-up from 9 different centers; mean defect 
size in the trial was 5.4 cm2 [37]. At final follow-up there was significant improvement in IKDC, 
VAS and SF-36 scores and a patient satisfaction rate of 80%. A total of 8 revision arthroscopies 
were performed for pain with 2 cases of implant hypertrophy and 2 cases of early failure [37]. 
In an imaging based outcome study, Welsch et al. compared 3T MRI results at 2 years for 
Hyalograft C versus CaReS and found greater T2 relaxation times for CaReS despite similar 
clinical outcomes between groups [38].
2.2.3. Novocart 3D
The Novocart 3D implant (B. Braun-Tetec, Reutlingen, Germany) is a collagen-chondroitin sul-
fate sponge (Table 4). After chondrocyte harvest, cells are initially cultured in a monolayer and 
then seeded onto the collagen-chondroitin sulfate scaffold at a density of 0.5–3.0 × 106 cells/cm2, 
after which the scaffold is cultivated in serum for 2 days before shipment for re-implantation 
[39]. Niethammer et al. performed several MRI-based studies of graft maturation and graft 
filling with Novocart 3D. In a 3 years prospective MRI study, graft maturation as assessed by 
T2 mapping required at least 1 year [40]. In a 2 years prospective MRI study, incomplete graft 
filling as assessed by MRI was common (55.7%) at 2 years and did not correlate with clinical 
results; the authors noted that graft thickness appeared to increase throughout the 2 years 
follow-up period [41]. A 2 years follow-up MRI study showed a 25% graph hypertrophy rate 
in Novocart 3D patients (11/44 patients), with higher hypertrophy rates in cases of acute trau-
matic defects or osteochondritis dissecans [42].
In a small non-randomized comparative study, Panagopoulos et al. report outcomes of Novocart 
3D (n = 9) and ACI-P (periosteal cover) (n = 11) and mean 37.5 months follow-up (Table 5) [43]. 
No significant difference in Tegner, Lysholm, or IKDC scores was noted between groups. The 
patient population consisted of high demand athletes and soldiers, with low rates of return to 
pre-injury activity levels (6/19, 31.5%) [43]. In a comparative study of 40 pediatric (<20 years 
old) patients treated with Novocart 3D versus 40 matched adult historical controls who also 
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underwent Novocart for similar size/location lesions, both groups had significant improve-
ment in VAS and IKDC scores at 36 months, but the pediatric group had greater improvement 
than the adult group at final follow-up [44]. A case series of 23 patients with 2 years follow-up 
by Zak et al. report improvement in symptoms scores as well as activity scores versus baseline 
with use of Novocart 3D [39]. At final follow-up, hypertrophy was noted via MRI in 16% and 
incomplete filling (>50%) in 20% of patients [39]. A large case series by Angele et al. of 433 
patients with mean 6.9 months follow-up (max 2.5 years) found an 8.5% re-operation rate, a 
6% graft failure rate in patients with >12 months follow-up [45]. Finally, in a case series with 
2 years follow-up, Niethammer noted that clinical outcomes at 2 years were worse for patients 
who returned to sport/physical activities at earlier than 12 months after surgery [46].
2.3. Hyaluronic acid or fibrin based scaffolds
2.3.1. Hyalograft C
The Hyalograft C scaffold is based on the benzylic ester of hyaluronic acid (HYAFF 11; Fidia 
Advanced Biopolymers Laboratories, Padova, Italy) (Table 6). The resulting scaffold is a 
meshwork of 20 micrometer diameter fibers. The cells are cultured directly on the scaffold 
with resulting collagen II and aggrecan production [5]. The implant is naturally adhesive 
and does not require an additional adhesive at time of implantation. Clinical outcomes of 
Hyalograft C were encouraging, with superior results in comparison to microfracture [47] and 
comparable results to MACI [48] or traditional ACI with a periosteum cover (Table 7) [49]. 
However, production of this implant has been discontinued by the manufacturer in favor of 
further development of a single-stage delivery system (no published clinical outcomes data 
available for the single-stage system).
Commercial name Manufacturer Structure Expansion Availability
Hyalograft C Anika Therapeutics (Fidia 
Advanced Biopolymers 
Laboratories, Padova, 
Italy)
Benzylic ester of 
hyaluronic acid 
(HYAFF) combined 
with expanded 
patient cells
Cells seeded and 
cultured directly 
on scaffold
No longer 
commercially 
available; production 
discontinued
BioCart II Histogenics Corporation, 
Waltham, MA (merger 
with former supplier, 
ProChon Biotech)
Human fibrin 
and recombinant 
hyaluronic acid-
based scaffold
Cells cultured 
in human serum 
and growth 
factor FGF2v1, 
then seeded onto 
scaffold
Available in Italy, 
Greece, and Israel; 
ongoing clinical trials 
in the United States; 
not yet approved by 
the FDA
Chondron Sewon Cellontech, Seoul, 
Korea
Fibrin based gel Cells cultured 
in serum; at 
time of surgery, 
suspension is 
mixed 1:1 with 
fibrin
Available in Korea
AIFA, Italian Medicines Agency; FDA, U.S. Food and Drug Administration.
Table 6. Hyaluronic acid or fibrin-based scaffolds.
Cartilage Repair and Regeneration150
2.3.2. BioCart II
An implant called BioCart II (Histogenics Corporation, Waltham, MA formerly sup-
plied by ProChon Biotech prior to merger with Histogenics) is comprised of a scaffold 
of recombinant hyaluronan with fibrin to form a sponge (Table 6). Cells are initially cul-
tured in human serum with recombinant fibroblast growth factor 2 variant (FGF2v1) and 
then seeded onto the scaffold prior to implantation with a mini-open approach. A small 
1 year outcome study by Nehrer et al. of 8 patients demonstrated significant improve-
ment in IKDC and Lysholm scores; 3 patients had a transient effusion post-operatively 
and there were no clinical failures (Table 7) [50]. A case series by Eshed et al. of patients 
who underwent MRI evaluation at mean 17.3 months after surgery (range 6–48 months) 
found continued maturation of cartilage with time (>1 year versus <1 year) and higher 
IKDC scores in patients with >12 months follow-up and without a history of prior carti-
lage surgeries [51].
2.3.3. Chondron
The Chondron scaffold is a fibrin-based gel (Sewon Cellontech Co. Ltd., Seoul, Korea) (Table 6). 
Chondrocytes are first cultured separately in a specialized serum (CRM kit, Sewon Cellontech, 
Korea). At the time of surgery the serum and cultured chondrocytes are mixed 1:1 with fibrin 
and injected directly onto the defect. In addition to typical preparation of the defect for ACI, 
several holes are drilled into the subchondral bone to improve adherence [52]. Choi et al. report 
a multicenter study of 98 patients with mean 24 month follow-up treated with Chondron 
(Table 7) [52]. Symptom improvement increased with time, with greater improvement noted 
with >25 months follow-up versus <25 months. Complication rates were low with one early 
repeat operation (1%) and two cases of symptomatic catching (2%) [52]. Similar findings were 
reported in a series by Kim et al., with no graft-related complications among 30 patients at 
24 months follow up; a second look arthroscopy at 12 months showed nearly normal cartilage 
Level of 
evidence
Author Implant and sample 
size
Mean 
follow-up
Outcome
2 Kon et al. [47] 21 Hyalograft C; 20 
microfracture
7.5 years Return to sport was a median 8 months for 
microfracture, 12.5 months for Hyalograft 
C. Symptom improvement with microfracture 
deteriorated with time whereas Hyalograft C was 
durable.
3 Kon et al. [48] 22 Hyalograft C; 39 
MACI
5 years All patients 40 years or older, treated with mini-
open MACI or arthroscopic Hyalograft C. Overall 
failure rate 20%, similar symptom improvement 
seen in both treatment groups.
3 Ferruzzi et al. 
[49]
50 Hyalograft C; 48 
ACI-P
2–5 years Similar IKDC improvement at 2+ years. Greater 
symptom improvement in first 12 months in 
Hyalograft C (arthroscopic) group versus ACI-P 
(mini-open)
Table 7. MACT clinical outcome studies with hyaluronic acid or fibrin-based scaffolds.
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in 8/10 patients [53]. A small series by Konst et al. of 9 patients with osteochondral defects 
(mean depth 0.9 cm) treated with autologous bone grafting as well as Chondron showed satis-
factory short term results at 12 months; there was one treatment failure which was converted 
to a unicompartmental knee arthroplasty [54].
2.4. Alginate based scaffolds
2.4.1. Cartipatch
Cartipatch (TBF Tissue Engineering, Mions, France) is a MACT implant with a scaffold com-
posed of agarose and alginate (Table 8). Chondrocytes are first cultured in a monolayer and 
then mixed with a hydrogel of agarose and alginate. The hydrogel can be manipulated at 
37°C and will solidify around 25°C, allowing formation of complex/irregular shapes with the 
scaffold. A multicenter randomized trial with 2 years follow-up was recently published by 
Clave et al. (Table 9) [55]. In this study, 30 patients were randomized to Cartipatch and 25 to 
mosaicplasty; all patients had isolated high grade femoral condylar defects 2.5–7.5 cm2 in size. 
At 2 years, there was significantly greater improvement in IKDC scores with mosaicplasty 
than Cartipatch, though both groups had significant improvement over baseline. A total of 
12 adverse events were reported for the Cartipatch groups and six in the mosaicplasty group 
[55]. An earlier case series by Selmi et al. reported 2 years outcomes of 17 patients treated 
with Cartipatch with a mean defect size of 3 cm2 [56]. All patients had significant symptom 
improvement with no clinical failures; second look biopsies in 13 patients had mostly hyaline-
like cartilage in 62% of cases (8/13) [56].
Commercial 
name
Manufacturer Structure Expansion Availability
Cartipatch Tissue Bank of France 
(TBF) Tissue Engineering, 
Mions, France
Alginate-agarose 
hydrogel combined 
with autologous cells
Two-step procedure; 
reduces cell leakage 
and implantation 
time
Ongoing phase III 
clinical trials; not yet 
approved by the FDA
FDA, U.S. Food and Drug Administration.
Table 8. Alginate hydrogel.
Level of 
evidence
Author Implant and 
sample size
Mean 
follow-up
Outcome
1 Clave et al. [55] 30 Cartipatch; 25 
mosaicplasty
2 years Both groups showed improvement in IKDC scores 
over baseline though mosaicplasty had greater 
symptom improvement than Cartipatch at 2 years 
for femoral lesions 2.5–7.5 cm2.
4 Selmi et al. [56] 17 Cartipatch 2 years Multicenter study. Significant symptom 
improvement in all patients, no clinical failures. 
Second look biopsies showed mostly hyaline-like 
cartilage in 8/13 patients (62%).
Table 9. MACT clinical outcome studies with alginate-based scaffolds.
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2.5. Atelocollagen gel
2.5.1. Koken Atelocollagen Implant
The MACT technique with use of the Koken Atelocollagen Implant (Koken, Tokyo, Japan) is 
similar to the ACI-P (periosteum cover) technique, but chondrocytes are suspended in atelo-
collagen gel rather than a liquid to obtain uniform distribution of chondrocytes within the 
defect and theoretically reduce risk of leakage (Table 10). In this technique, after initial isola-
tion of chondrocytes from cartilage biopsy, the chondrocyte suspension is mixed 1:4 with a 
3% bovine atelocollagen solution (Koken, Tokyo, Japan) [57]. Chondrocytes are expanded in 
this mixture for 28 days; the final product (the Koken Atelocollagen Implant) is an opaque 
implant with a jelly-like consistency. The Koken Atelocollagen Implant is implanted with a 
mini-arthrotomy and requires a periosteum cover to contain the atelocollagen-based scaf-
fold within the defect [57]. A multicenter trial in Japan reported by Tohyama et al. reports 
use of the Koken Atelocollagen Implant and periosteum cover in 27 patients (Table 11) [57]. 
Overall there was a significant improvement in Lysholm scores at final 2 years follow-up. On 
second look arthroscopy, 24% of repair sites were ICRS grade normal and 48% were nearly 
normal. There was one case of graft hypertrophy, two cases of graft detachment, and two 
cases of abnormal or severely normal ICRS grade on second look arthroscopy [57]. Recently, 
Tadenuma et al. report clinical and imaging outcomes of 8 patients (11 knees) at mean 5.9 years 
after surgery [58]. The authors note significant improvement in Lysholm scores over baseline 
with one clinical failure (9%) and one traumatic repeat injury 7 years after surgery (9%). The 
authors report a correlation between T1 values of the repair site on MRI and clinical outcomes 
but no correlation between T2 values and outcomes [58].
Commercial name Manufacturer Structure Expansion Availability
Koken 
Atelocollagen 
Implant
Koken, Tokyo, 
Japan
Atelocollagen gel 
(3% type 1 bovine 
collagen gel)
Chondrocyte suspension is initially 
mixed 1:4 with 3% atelocollagen 
solution. The mixture is cultured for 
4 weeks and thickens to a jelly-like 
consistency over that time.
Available in 
Japan
Table 10. Atelocollagen based scaffold.
Level of 
evidence
Author Implant and 
sample size
Mean 
follow-up
Outcome
4 Tohyama et al. [57] 27 Koken 
Atelocollagen 
Implant
2 years Multicenter study. Symptom scores (Lysholm) 
improved at 2 years from baseline. Two cases of 
graft detachment (7.4%). Two remaining cases 
were graded abnormal or severely abnormal on 
second look arthroscopy (8%, 2/25).
4 Tadenuma et al. [58] 11 Koken 
Atelocollagen 
Implant
5.9 years Improved Lysholm scores at final follow-up with 
one clinical failure (9%). T1 scores on MRI at final 
follow-up correlated with clinical scores but T2 
scores did not.
Table 11. MACT clinical outcome studies with alginate-based scaffolds.
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2.6. Polyglycolic/polylactic acid and polydioxanone based scaffold
2.6.1. BioSeed-C
The BioSeed-C (BioTissue Technologies GmbH, Freiburg, Germany) MACT scaffold is 
comprised polyglycolic/polylactic acid (polyglactin, vicryl), and polydioxanone (Table 12). 
Harvested chondrocytes are first expanded in serum and then seeded into the polymer scaf-
fold with fixation by fibrin. The scaffold is available in a standard rectangular shape (2 cm 
× 3 cm × 0.2 cm thickness) can be implanted arthroscopically or with a mini-arthrotomy. 
The defect must be contoured to a rectangular shape (more than one scaffold can be used as 
needed for larger defects) and corners of the scaffold are secured with transosseous resorb-
able suture loops [59].
In a comparative non-randomized study of ACI-P versus BioSeed-C with minimum 2 years 
follow up, Erggelet et al. report similar improvement in symptom scores (Table 13) [60]. 
The graft failure rate was similar between groups (3/42 ACI-P; 2/40 BioSeed-C), but re-
operation rates were twice as high in the ACI-P group, primarily due to graft hypertrophy 
[60]. A smaller randomized study of ACI-P (n = 10) versus BioSeed-C (n = 9) with 2 years 
follow-up by Zeifang et al. found similar improvement in symptoms between groups (per 
IKDC score) at both 1 and 2 years [61]. In contrast to the findings reported by Erggelet et al. 
[60], re-operation rates were higher in the BioSeed C group (3/11 patients) versus ACI-P 
(1/10 patients) [61].
Commercial 
name
Manufacturer Structure Expansion Availability
BioSeed-C BioTissue AG (BioTissue 
Technologies, GmbH, 
Freiburg, Germany)
Fibrin, polyglycolic/polylactic acid 
and polydioxanone-based material 
combined with culture-expanded 
autologous chondrocytes and 
suspended in fibrin.
Chondrocytes 
cultured in serum 
then subsequently 
seeded into scaffold.
CE mark 
approval; not 
yet approved 
by the FDA.
CE, Conformité Européenne; FDA, U.S. Food and Drug Administration.
Table 12. Scaffolds with polyglycolic/polylactic acid and polydioxanone.
Level of 
evidence
Author Implant and 
sample size
Mean 
follow-up
Outcome
2 Zeifang et al. [61] 11 BioSeed-C; 9 
ACI-P
2 years Similar IKDC symptom improvement in both 
groups at 1 year and 2 years. Higher re-operation 
rate in BioSeed C group.
3 Erggelet et al. [60] 40 BioSeed-C; 42 
ACI-P
36 m ACI-P
24 m 
BioSeed-C
Twice as many re-operations required for ACI-P 
versus BioSeed-C. Three graft failures in ACI-P 
group and two in BioSeed-C group. Equivalent 
improvement in symptom scores between 
groups.
Table 13. MACT clinical outcome studies with polyglycolic/polylactic acid and polydioxanone based scaffold.
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Several case series have also been reported for BioSeed-C (Table 13). Ossendorf et al. report 
a case series of 40 patients treated with BioSeed-C with 2 years follow-up; symptom scores 
were significantly improved at both 1 and 2 years after baseline [59]. Reoperations occurred in 
12.5% of patients including synovectomy (n = 2), debridement (n = 1), total knee arthroplasty 
(n = 1), and graft removal (n = 1) [59]. The mid-term outcomes of the same patient cohort with 
4-years follow-up were reported by Kreuz et al. [62]. The authors note a durable symptom 
improvement over 4 years and a high rate of graft filling (mostly or completely filled in 43/44 
patients on MRI assessment) [62]. In the subgroup analysis of 19 patients in this cohort with 
baseline osteoarthritis and a high grade focal defect, Kreuz et al. noted symptom improve-
ment at 6–12 months which remained stable at 4 years as well as two clinical failures that went 
on to total knee arthroplasty (10.5%) [63].
3. Conclusions
In conclusion, short and mid-term clinical outcomes studies of MACT therapies for cartilage 
defects of the knee have been encouraging. However, commercial availability of MACT pro-
cedures is highly variable with respect to geographic region. Recent approval was granted 
in December 2016 by the FDA for use of MACI in the United States. To date this is the only 
MACT therapy available in this region. Availability is greater for multiple MACT therapies 
in Europe, though European Medicine Agency marketing approval for MACI was recently 
suspended in June 2016.
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